Beyond Dopamine: Why Traditional Schizophrenia Treatments Miss 50% of Patient Needs
Wed Feb 04 2026
In this episode of Power to the Patients, Brandon Li sits down with Dr. Laxminarayan Bhat, Founder and CEO of Reviva Pharmaceuticals, to explore groundbreaking developments in schizophrenia treatment. Dr. Bhat shares insights on his company's innovative drug that shows promising results with fewer side effects and better patient adherence than existing treatments. Discover how their unique approach to targeting serotonin-dopamine signaling, combined with reduced off-target effects, could transform the lives of millions living with schizophrenia. Learn about the challenges and triumphs of developing psychiatric medications, the role of biomarkers in treatment, and the future of precision psychiatry.
More
In this episode of Power to the Patients, Brandon Li sits down with Dr. Laxminarayan Bhat, Founder and CEO of Reviva Pharmaceuticals, to explore groundbreaking developments in schizophrenia treatment. Dr. Bhat shares insights on his company's innovative drug that shows promising results with fewer side effects and better patient adherence than existing treatments. Discover how their unique approach to targeting serotonin-dopamine signaling, combined with reduced off-target effects, could transform the lives of millions living with schizophrenia. Learn about the challenges and triumphs of developing psychiatric medications, the role of biomarkers in treatment, and the future of precision psychiatry.